Why Did Jounce Therapeutics (JNCE) Stock Gain 72% Today?
Following an amendment in a strategic agreement, shares of Jounce Therapeutics Inc. (JNCE) increased 59.75% to $1.18 on Wednesday. Which agreement has JNCE amended? In an announcement made yesterday, Jounce Therapeutics (JNCE) stated that it has modified its current license arrangement with Gilead Sciences Inc. (GILD) for GS-1811 (formerly JTX-1811). Gilead will now be entitled […]